IL1B and type 2 diabetes mellitus: Furthermore, SGLT-2 inhibitors significantly reduce the levels of IL-1β and IL-18, consistent with reduced activity of the NLRP3 inflammasome, leading to reduced adverse cardiac events in patients with T2D and CVD in a β-hydroxybutyrate- (BHB-) dependent manner [143].